Correspondence
We acknowledge the letter from Drs Rao and Chan for highlighting the limitations pertinent to clinical applicability of our findings, and we acknowledge Drs Proietti, Thanassoulis, and Essebag for sharing their case of a patient who suffered a stroke after cardiovascular implantable electronic device implantation. 1 The former letter expresses concern regarding the potential for misclassification bias attributable to differential diligence in diagnosing patients with patent foramen ovale (PFO) already at high risk for cardioembolism. The latter suggests that characteristics of the PFO themselves, such as the size and degree of shunting, may affect the risk attributable to PFOs.
We reviewed all transthoracic and transesophageal echocardiogram (TEE) reports available for patients who had cardiovascular implantable electronic devices implanted at Mayo Clinic Rochester between January 1, 2000, and October 25, 2010, for mention of PFO and whether the PFO was definite or could not be conclusively confirmed or refuted. Only patients with conclusive PFOs whether with TEE, color Doppler, or agitated saline contrast were considered eligible for the PFO group, and the cases with inconclusive reports were excluded from analysis. Because many patients had multiple echocardiograms with >1 clinical indication listed in the reports and with >6000 patients (with some patients with >40 echocardiographic reports available for review), we were unable to systematically analyze the clinical indications for the studies performed. We speculate that agitated saline contrast was used either as a reflex when PFO was suspected on color Doppler examination or in the presence of a mobile interatrial septum or atrial septal aneurysm, or as standard practice for comprehensive evaluations by certain echocardiographers, and on a more routine basis during comprehensive TEEs.
It is noteworthy that we excluded all cases in which PFO diagnosis was made within 30 days after a stroke/transient ischemic attack (TIA) event, biasing our results toward null. If we had included the cases of possible/probable PFO (74 patients) and poststroke/TIA diagnoses of PFO (11 patients), the PFO rate would have increased to 7.3% as opposed to 6% (still lower than the expected 10% to 15%). 2 In addition, although there was probably an underdiagnosis of PFOs in our study, random underdiagnoses alone would only bias toward null by counting some PFO-related stroke/TIA events in the non-PFO group. Only a systematic misclassification by more thorough evaluation for PFO among patients with future stroke/TIA events based on unmeasurable prior concern would bias toward a false-positive association. We are unable to quantify such a bias related to differential use of agitated saline contrast. However, patients experiencing stroke/TIA subsequent to cardiovascular implantable electronic device implantation had higher rates of prior TEE evaluations (32.7% versus 12.1%). This difference in TEE rates was presumably partially in the context of prior stroke/TIA symptoms. The bias attributable to this would be on the order of an absolute 2% difference in stroke/TIA in the PFO versus non-PFO group compared with the 14.8% observed in our study. Moreover, we adjusted for prior stroke/TIA in our multivariable proportional hazards analysis.
We are not as surprised by the rate of warfarin use being 32% in our "real-world" population, when atrial fibrillation was clinically diagnosed in 45%. 3 Some patients, despite the overall mean CHA 2 DS 2 -VASc score of 3, would have a low score to not warrant anticoagulation, whereas others might have personal or other clinical reasons to not use warfarin. We would like to emphasize that in our subgroup analysis, PFO was associated with increased risk of stroke whether or not atrial fibrillation, high CHA 2 DS 2 -VASc score, or baseline warfarin use was present.
In our study on patients with cardiovascular implantable electronic devices, congestive heart failure (present in 46% of the study population) was not associated with stroke/TIA (P=0.27), and PFO association with stroke/TIA was independent of congestive heart failure. We have further analyzed our PFO cohort and found no significant difference from baseline to longest-term follow-up with respect to ejection fraction percentage and right ventricular systolic pressure. 4 Estimated right ventricular systolic pressure was 41.7±12.8 mm Hg at baseline and 42.1±14.1 mm Hg at follow-up (P=0.60). Ejection fraction percentage at baseline was 45.5±17.6 mm Hg versus 46.4±17.0 mm Hg at follow-up (P=0.20). Furthermore, neither right ventricular systolic pressure (hazard ratio=0.99; P=0.55) nor ejection fraction (hazard ratio=1.02; P=0.153) was associated with an increase in stroke/TIA on univariate analysis. 4 Defibrillators were implanted in 43% of patients, and the rest had pacemakers. Furthermore, among patients who had a PFO diagnosis, defibrillation coils were not associated with risk of stroke/TIA (P=0.65). 5 In summary, we agree with caution against overinterpretation of our findings in clinical situations. However, until a prospective evaluation can provide further data, when a PFO is documented we would urge physicians to consider our findings for an informed discussion when recommending endovascular lead implantation.
